You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Based on expression patterns in mouse strains with variable infection susceptibility, investigators came up with a signature that predicted Ebola virus response in West Africa patients.
In Cell this week: B cell responses in Ebola survivors, two mRNA anti-terminator proteins, and more.
Researchers trained a machine-learning model to predict animal reservoirs or insect vectors for dozens of "orphan" viruses with unknown natural sources.
In PNAS this week: population structure in Helicoverpa, AMP-activated protein kinase levels in nicotine-exposed mice, and more.
The researchers found that the expression of certain genes was better at helping them predict when Ebola would develop than indications of infection like fever.
The Fraunhofer USA team will partner with a Fraunhofer Society institute in Germany in order to reduce the cost for its patented microchip that detects viruses including Ebola.
In PLOS this week: approach to diagnose hemorrhagic fevers, recessive disease mutations in mixed-breed dogs, and more.
The researchers found multiple enzymes that indicate causes of dysregulated adaptive immunity and tissue damage in fatal Ebola virus disease.
The German company said the open-access platform, called Pharos V8, can provide real-time PCR results in 10 minutes.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.